Autobio Diagnostics (SHA:603658) said it obtained medical device registration certificates from China's National Medical Products Administration for three diagnostic kits, according to a Friday filing with the Shanghai Bourse.
The kits include an HER-2/neu test for breast cancer monitoring, a Group B Streptococcus DNA test for pregnant women, and an H. pylori IgG antibody test.
The approvals expand Autobio's product portfolio and enhance market competitiveness.